Related references
Note: Only part of the references are listed.Quantifying the impact of COVID-19 on essential health services: a comparison of interrupted time series analysis using Prophet and Poisson regression models
William Ogallo et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2023)
Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029
Clara Marquina et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)
Trajectories of prices in generic drug markets: what can we infer from looking at trajectories rather than average prices?
Antonio J. Trujillo et al.
HEALTH ECONOMICS REVIEW (2022)
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Roger Chou et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Gazing through time and beyond the health sector: Insights from a system dynamics model of cardiovascular disease in Australia
Cindy Q. Peng et al.
PLOS ONE (2021)
Statins Do More Than Lower Cholesterol-Depending on What You Eat?
Thomas Eschenhagen et al.
CIRCULATION (2021)
STATIN THERAPY IS ASSOCIATED WITH BETTER 24-HOUR AND NIGHT-TIME BLOOD PRESSURE CONTROL IN HYPERTENSIVE PATIENTS
Francesco Spannella et al.
JOURNAL OF HYPERTENSION (2021)
Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018
Shuo-yu Lin et al.
JAMA NETWORK OPEN (2021)
Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation
Veronique C. Raimond et al.
MILBANK QUARTERLY (2021)
Evolving worldwide approaches to lipid management and implications for Australian general practice
Tom Brett et al.
Australian Journal of General Practice (2021)
The Evolution of Supply and Demand in Markets for Generic Drugs
Richard G. Frank et al.
MILBANK QUARTERLY (2021)
Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses
Ting Cai et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Strategies to achieve fairer prices for generic and biosimilar medicines
Alessandra Ferrario et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
ACC/AHA lipid guidelines: Personalized care to prevent cardiovascular disease
Cara Reiter-Brennan et al.
CLEVELAND CLINIC JOURNAL OF MEDICINE (2020)
2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease
Martin Bodtker Mortensen et al.
EUROPEAN HEART JOURNAL (2020)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019 Update From the GBD 2019 Study
Gregory A. Roth et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Autonomy, power dynamics and antibiotic use in primary healthcare: A qualitative study
Laura Medina-Perucha et al.
PLOS ONE (2020)
2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease
Martin Bodtker Mortensen et al.
EUROPEAN HEART JOURNAL (2020)
Medication adherence influencing factors-an (updated) overview of systematic reviews
Alina Gast et al.
SYSTEMATIC REVIEWS (2019)
Estimating the future health and aged care expenditure in Australia with changes in morbidity
Anthony Harris et al.
PLOS ONE (2018)
Effectiveness of programs to promote cardiovascular health of Indigenous Australians: a systematic review
Vainess Mbuzi et al.
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH (2018)
Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks
Toon van der Gronde et al.
PLOS ONE (2017)
Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme
Jonathan Karnon et al.
AUSTRALIAN HEALTH REVIEW (2017)
A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study
Francine K. Welty et al.
JOURNAL OF WOMENS HEALTH (2016)
Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
Sabine Vogler et al.
LANCET ONCOLOGY (2016)
Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme
L. P. Thai et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2016)
Generic drug prices and policy in Australia: room for improvement? A comparative analysis with England
Sarah J. Mansfield
AUSTRALIAN HEALTH REVIEW (2014)
The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use
Mohamed Azmi Hassali et al.
SAUDI PHARMACEUTICAL JOURNAL (2014)
Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy
Jean Spinks et al.
AUSTRALIAN HEALTH REVIEW (2013)
Challenges and opportunities for the Pharmaceutical Benefits Scheme
Philip M. Clarke
MEDICAL JOURNAL OF AUSTRALIA (2012)
Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia
Philip M. Clarke et al.
MEDICAL JOURNAL OF AUSTRALIA (2010)